Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
PharmaCompass finds 500 drugs with ‘no patents and no competition’ in the FDA Orange Book
In April last year, PharmaCompass
had shared a list of over 300
different dosage forms of drugs whic
Drugs with no patents and no competition – here’s our list of new ‘price-gouging’ targets
Drug price increases have emerged as a core strategy for generic pharmaceutical companies in the rec
